The incidence of pregnancy in women with cardiovascular disease is rising, primarily due to the increased number of women with congenital heart disease reaching childbearing age and the changing demographics associated with advancing maternal age. Although most cardiac conditions are well tolerated during pregnancy and women can deliver safely with favorable outcomes, there are some cardiac conditions that have significant maternal and fetal morbidity and mortality. The purpose of this paper is to review the available published reports and provide recommendations on the C ardiovascular disease has been estimated to be present in 1% to 4% of pregnancies. The incidence of pregnancies in women with heart disease is rising, mainly due to an increased number of women with congenital heart disease (CHD) reaching childbearing age; advancing maternal age; and increased incidence of risk factors, including diabetes mellitus, hypertension, pre-eclampsia, and multifetal pregnancies.
C ardiovascular disease has been estimated to be present in 1% to 4% of pregnancies. The incidence of pregnancies in women with heart disease is rising, mainly due to an increased number of women with congenital heart disease (CHD) reaching childbearing age; advancing maternal age; and increased incidence of risk factors, including diabetes mellitus, hypertension, pre-eclampsia, and multifetal pregnancies.
Although the majority of women with cardiac disease can become pregnant and, with early diagnosis and appropriate management, can be brought to term safely, there are high-risk cardiac conditions that may be associated with important morbidity, and even mortality. With increased numbers of pregnancies in women with cardiac problems, heart disease has emerged as the leading cause of nonobstetric maternal mortality. This state-of-the-art review is focused on the approach to pregnancy in women with cardiac conditions associated with high maternal and fetal risks (Central Illustration).
NORMAL CARDIAC PHYSIOLOGY OF PREGNANCY
Blood volume increases substantially during pregnancy, starting as early as the sixth week and rising rapidly until midpregnancy, when the rise continues at a slower rate, with an average maximum increase of 50% (1, 2) (Figure 1 ). Because the red blood cell mass increases less rapidly, the hemoglobin concentration falls, causing the "physiological anemia of pregnancy." Cardiac output (CO) during pregnancy increases by about 50%, predominantly due to augmentation of stroke volume during early pregnancy and increased heart rate in the third trimester.
Systemic blood pressure (BP) falls during the first trimester, reaching a nadir in midpregnancy and returning toward pre-gestational levels before term.
This change results from a decline in systemic vascular resistance due to reduced vascular tone.
Hemodynamics are altered substantially during labor and delivery, secondary to anxiety, pain, and uterine contractions. Oxygen consumption increases 3-fold, and systolic and diastolic BP rise during contractions.
Reduction of pain and apprehension with analgesia and anesthesia may limit hemodynamic changes and the rise in oxygen consumption. Cesarean delivery is frequently recommended in women with cardiac disease; however, it can be also associated with considerable hemodynamic changes related to intubation and drugs used for anesthesia. A temporary increase in intracardiac pressures may occur immediately after delivery due to relief of caval compression and blood shift from the contracting uterus into the systemic circulation, which may lead to clinical deterioration.
PREGNANCY RISK ASSESSMENT
Assessment of pregnancy risk is an important aspect of the care of women with heart disease who are of childbearing age (3) . All women with cardiac disease can benefit from pre-conception counseling, which should include a detailed discussion of the risk of pregnancy. Some women may require optimization of cardiac status prior to pregnancy, and for those women considering pregnancy, cardiac medications that are teratogenic, such as warfarin and angiotensinconverting enzyme inhibitors, can be switched to safer medications when necessary. Increasing numbers of women with heart disease are considering fertility therapy, and in this circumstance, preconception risk stratification and safety of fertility therapy should be addressed. A discussion of safe contraception choices is relevant for those who decide not to become pregnant. It is important that this information is communicated effectively to patients; a number of groups have shown that many women do not fully understand pregnancy and contraception risks (3) (4) (5) .
Cardiologists with expertise in pregnancy and heart disease should perform pre-conception counseling and risk stratification. Issues to address at the time of pre-conception counseling are shown in Table 1 . Risk assessment should include a complete history and physical examination, a 12-lead electrocardiogram (ECG), and a transthoracic echocardiogram. In women who are pregnant, signs and symptoms of pregnancy can mimic heart disease, and should be interpreted accordingly. Risk stratification may be further defined by incorporating other clinical and imaging information, including disease activity, cardiac computed tomography (CT), or cardiac magnetic resonance. Cardiac magnetic resonance and CT findings should be reviewed and incorporated into risk assessment, especially in women with aortopathies and complex congenital lesions.
Exercise stress testing to measure functional capacity and BP response to exercise is useful for risk stratification in women with valve lesions, such as aortic stenosis (AS) (6, 7) .
Cardiopulmonary testing, with measurements of oxygen saturation, functional capacity, peak VO 2 , and chronotropic index, provides helpful information in women with complex CHD (8) . Baseline and serial serum B-type natriuretic peptide levels during pregnancy can be incorporated into pregnancy assessment in women with the potential to develop heart failure (HF) during pregnancy due to myocardial disease, valvular heart disease, and CHD. In specific cases, women with arrhythmias may benefit from continuous ECG monitoring, exercise testing, or electrophysiology studies. Women with inherited cardiac conditions should have a formal genetic evaluation to discuss transmission of disease to offspring (6, 9) . Autosomal-dominant cardiac conditions include Marfan, Noonan, William, Holt-Oram, and 22q11 deletion syndromes, as well as some of the inherited arrhythmias (long-QT syndrome) and cardiomyopathies (hypertrophic cardiomyopathy).
Women with inherited cardiac conditions who have an identified genetic mutation may wish to explore the option of pre-implantation genetic screening.
Assessment with maternal fetal medicine specialists (high-risk obstetricians) to discuss obstetric risk is an important part of pre-conception assessment.
To estimate pregnancy risk, it is important to consider general and lesion-specific risk predictors.
General risk predictors are relevant for all women with heart disease and include factors such as cardiac history, functional capacity, and ventricular function.
Lesion-specific risks are known for many, but not all, cardiac conditions and are discussed later, in the corresponding sections.
For women with pre-existing heart disease, the most common cardiac complications during pregnancy are arrhythmias, HF, and thromboembolic events (TEs). Early studies on pregnancy risk predictors identified functional class and cyanosis as important determinants of adverse outcomes during pregnancy (10) (11) (12) . Subsequently, large pregnancy cohorts were assembled, and pregnancy risk indexes were developed (13) (14) (15) (16) (17) (18) (19) , which are shown in Table 2 .
The first prospective risk index was developed by the CARPREG (Cardiac Disease in Pregnancy) investigators. The CARPREG study examined outcomes in women with congenital and acquired heart disease and identified 4 predictors of adverse maternal 
CENTRAL ILLUSTRATION High-Risk Heart Disease in Pregnancy
Pre-conception counseling and pregnancy risk stratification for all women with HRHD of childbearing age
In women considering pregnancy: Switch to safer cardiac medications and emphasize importance of close monitoring
In women avoiding pregnancy: Discuss safe and effective contraception choices or termination in early pregnancy
Valve disease
Complex congenital heart disease Pulmonary hypertension Aortopathy Dilated cardiomyopathy
Pregnancy not advised in women with:
• Severe mitral and aortic valve disease
• Mechanical prosthetic valves if effective anticoagulation not possible
• Significant ventricular dysfunction
• Severe atrioventricular valve dysfunction
• Failing Fontan circulation
• O 2 saturation <85%
Pregnancy not advised for:
• All women with established pulmonary arterial hypertension
Pregnancy not advised in some women with:
• Marfan syndrome (MFS)
• Bicuspid aortic valve (BAV)
• Turner syndrome
• Rapid growth of aortic diameter or family history of premature aortic dissection
• Left ventricular ejection fraction <40%
• History of peripartum cardiomyopathy
Pregnancy management:
• Close follow-up
• Drug therapy for heart failure or arrhythmias
• Balloon valvuloplasty or surgical valve replacement in refractory cases
• Early institution of pulmonary vasodilators
• Treat hypertension
• Beta-blockers to reduce heart rate
• Frequent echo assessment
• Surgery during pregnancy or after C-section if large increase in aortic dimension
• Beta-blockers
• Diuretic agents for volume overload
• Vasodilators for hemodynamic and symptomatic improvement Delivery:
• Vaginal delivery preferred
• C-section in case of fetal or maternal instability
• Early delivery for clinical and hemodynamic deterioration
• Consider hemodynamic monitoring during labor and delivery
Delivery:
• C-section in case of fetal or maternal instability Obstetric and perinatal outcomes risks also need to be considered. Women with heart disease are at risk for obstetric complications (22, 23) . In 1 study of women with CHD, adverse obstetric events (pre-term delivery, premature rupture of the membranes, postpartum hemorrhage) occurred in 32% of pregnancies (21) . Miscarriages are common in women with cyanotic heart disease or Eisenmenger syndrome.
Live birth rates are low in women with cyanotic heart disease, occurring in only 43% of pregnancies overall and 12% of pregnancies in women with oxygen saturations #85% (24) . Women with coarctation of the aorta are at increased risk for hypertension, preeclampsia, and HF (25) . Bleeding at the time of delivery is more common in women with cyanotic heart disease and in women taking anticoagulants. Fetal and neonatal deaths, premature births and associated complications (respiratory distress syndrome or intraventricular hemorrhage), and small-forgestational-age birth weight babies are more common in women with heart disease compared with "healthy" women (14, 15, 17 lesions (14, 26) . Although most women are aware of their diagnosis prior to pregnancy, some present for the first time during pregnancy. Occasionally, women come to attention when a murmur is detected. Bicuspid valve disease may be associated with aortic root dilation or coarctation of the aorta, and these may confer additional pregnancy risks. Less frequently, AS is secondary to rheumatic heart disease. The increased CO of pregnancy may be poorly tolerated in the setting of a fixed outflow obstruction.
At the time of labor and delivery, relief of inferior vena cava compression, autotransfusions from the contracting uterus, and excessive intravenous fluid administration may also be poorly tolerated.
Women with mild or moderate AS often do well, whereas women with severe AS can develop angina, tachyarrhythmias, and pulmonary edema (27, 33, 41) . Maternal mortality is rare (<1%) in contemporary pregnancy series (27, 33, 41) . Pregnancies in women
Pregnancy and Heart Disease: Part I with significant AS are associated with high rates of pre-term delivery, low birth weight, and fetal death (27, 33, 41 (27, 42) . The mechanism for these high rates of valve intervention after pregnancy is not known. 
PROSTHETIC HEART VALVES
Pregnancy in women with prosthetic heart valves (PHVs) has been shown to be associated with a substantial risk of morbidity and even mortality (51, 52) .
The choice between a bioprosthetic heart valve (BPHV) and a mechanical prosthetic heart valve (MPHV) in women of childbearing age is difficult. The use of BPHVs in young women is often recommended Pregnancy and Heart Disease: Part I J U L Y 2 6 , 2 0 1 6 : 3 9 6 -4 1 0 pregnancy-related increased incidence of structural valve deterioration in women with BPHVs (51).
Because a second valve replacement is almost mandatory in young women who elect to receive a BPHV, the risk of a second and possibly a third cardiac valve operation needs to be taken into account. Transcatheter aortic valve replacement for deteriorated bioprosthetic aortic valve has been increasingly and successfully used in older patients (57).
However, no information is available about the safety and durability of such a procedure in young women. Class I 1. Therapeutic anticoagulation with frequent monitoring is recommended for all pregnant patients with a mechanical prosthesis (Level of Evidence: B). 2. Warfarin is recommended in pregnant patients with a mechanical prosthesis to achieve therapeutic INR in the second and third trimesters (Level of Evidence: B). 3. Discontinuation of warfarin with initiation of intravenous UFH (with an aPTT >2Â control) is recommended before planned vaginal delivery in pregnant patients with a mechanical prosthesis (Level of Evidence: C). 4. Low-dose aspirin (75-100 mg) once per day is recommended for pregnant patients in the second and third trimesters with either a mechanical prosthesis or bioprosthesis (Level of Evidence: C). Class IIa 1. Continuation of warfarin during the first trimester is reasonable for pregnant patients with a mechanical prosthesis if the dose of warfarin to achieve a therapeutic INR is #5 mg/day, after full discussion with the patient about risks and benefits (Level of Evidence: B)* 2. Dose-adjusted LMWH at least twice per day (with a target anti-Xa level of 0.8 U/ml to 1.2 U/ml, 4 to 6 h post-dose) during the first trimester is reasonable for pregnant patients with a mechanical prosthesis if the dose of warfarin is >5 mg/day to achieve a therapeutic INR (Level of Evidence: B)* 3. Dose-adjusted continuous intravenous UFH (with an aPTT at least 2Â control) during the first trimester is reasonable for pregnant patients with a mechanical prosthesis if the dose of warfarin is >5 mg/day to achieve a therapeutic INR (Level of Evidence: B)* European Society of Cardiology 2011 (6) Class I C OACs are recommended during the second and third trimesters until the 36th week. Change of anticoagulation regimen during pregnancy should be implemented in hospital.
If delivery starts while on OACs, cesarean delivery is indicated. OAC should be discontinued and dose-adjusted UFH (aPTT 2Â control) or adjusted-dose LMWH (target anti-Xa level 4-6 h post-dose 0.8-1.2 U/ml) started at the 36th week of gestation.
In pregnant women managed with LMWH, the post-dose anti-Xa level should be assessed weekly.* LMWH should be replaced by intravenous UFH at least 36 h before planned delivery. UFH should be continued until 4-6 h before planned delivery and restarted 4-6 h after delivery if there are no bleeding complications. Immediate echocardiography is indicated in women with mechanical valves presenting with dyspnea and/or an embolic event. Class IIa C Continuation of OACs should be considered during the first trimester if the warfarin dose required for therapeutic anticoagulation is <5 mg/day (or phenprocoumon <3 mg/day or acenocoumarol <2 mg/day), after patient information and consent.* Discontinuation of OACs between weeks 6 and 12 and replacement by adjusted dose UFH (aPTT >2Â control in high-risk patients applied as intravenous infusion) or LMWH twice daily (with dose adjustment according to weight and anti-Xa level 4-6 h post-dose 0.8-1.2 U/ml) should be considered in patients with a required warfarin dose >5 mg/day (or phenprocoumon >3 mg/day or acenocoumarol >2 mg/day).* Class IIb C Discontinuation of OACs between weeks 6 and 12, and replacement by UFH or LMWH under strict dose control (as described earlier), may be considered on an individual basis in patients with a warfarin dose required for therapeutic anticoagulation >5 mg/day (or phenprocoumon >3 mg/day or acenocoumarol >2 mg/day).* Continuation of OACs may be considered between weeks 6 and 12 in patients with a warfarin dose required for therapeutic anticoagulation >5 mg/day (or phenprocoumon <3 mg/day or acenocoumarol <2 mg/day).* Class III C LMWH should be avoided unless anti-Xa levels are monitored.
and valve motion (86) . Valve These complications are further increased in patients requiring urgent surgery (31, (90) (91) (92) .
PREGNANCY-ASSOCIATED ACUTE MYOCARDIAL INFARCTION
There is a 3-fold increase in the incidence of acute myocardial infarction (AMI) during pregnancy and the peripartum period (PP) compared to that seen in nonpregnant women of similar age (93) . Most recent nationwide inpatient samples for pregnancy-related discharges showed an incidence of 1 in 16,000 deliveries (94) . Myocardial infarction related to pregnancy occurs in all ages, but the majority of women are Table 3 . Warfarin (INR 2.5-3.5) for 36 weeks, followed by IV UFH (aPTT >2.5) to parturition þ ASA 81-100 mg/day. OR LMWH SC Q12 h (trough anti-Xa $0.7 IU/ml, peak anti-Xa <1.5 IU/ml) for 12 weeks, followed by warfarin (INR: 2.5-3.5) to 36 weeks then UFH IV (aPTT >2.5) to parturition þ ASA 81-100 mg/day.
Lower Risk: New-Generation MPHV in Mitral and Aortic Positions LMWH SC Q12 h (trough anti-Xa $0.6 IU/ml, peak anti-Xa <1.5 IU/ml) for 36 weeks, followed by IV UFH (aPTT >2.5) to parturition.
older than 30 years of age. There is also a relatively high incidence of traditional risk factors for coronary artery disease, despite the young age, including hyperlipidemia, hypertension, obesity, and diabetes (93) . In addition, pre-eclampsia and eclampsia have been suggested as additional risk factors (94) . Pregnancy-associated myocardial infarction presents in the majority of cases as ST-segment elevation myocardial infarction (STEMI), and has been reported to involve the anterior wall in 70% to 80% of patients. As a result, there was a significant reduction of LV ejection fraction (>40%) in >50% of cases, and a high incidence of HF, cardiogenic shock, and ventricular arrhythmias (95) . Maternal mortality was reported in 3 recent trials to be between 5% and 7% (95), a rate 2-to 3-fold higher than that reported in women with AMI who were <55 years of age (97) .
Fetal mortality was reported in the most recent study to be 5%, and was mostly associated with maternal mortality (95) . should be reserved for cases where the potential benefit outweighs the increased risk (95) . CT coronary angiography may provide a safer method to obtain anatomic information, but it is also associated with hazards related to fetal radiation and a need to use high doses of a beta-blocker for appropriate heart rate reduction.
The conservative approach seems advisable in stable patients with SCAD. This recommendation is Information on the safety of cardiac drugs is provided in 
